RxDoctor Payments Data

Jonathan Finegold, MD

Gastroenterology · Bronxville, NYNPI 1336206846

Payments from drug & device makers

$4,108in general payments, 2019–2025

Across 117 payments — averaging $35.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$1K
  • AbbVie$977
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$573
  • Bristol Myers Squibb$308
  • Braintree Laboratories, Inc.$301
  • Celltrion USA Inc.$258
  • plus $616 from 7 others

What the payments were for

  • Food & beverage$4,100100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,108 in reported general payments places this provider in the 60th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$150,540
Medicare patients
373
Services billed
652

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SutabSod Sulf/Pot Chloride/Mag Sulf77$12,276
Mesalamine15$11,603
Omeprazole441$6,739
Mesalamine ErMesalamine48$6,731
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates83$5,059
Dexlansoprazole DrDexlansoprazole15$3,492
Famotidine152$2,447
ClenpiqSod Picosulf/Mag Ox/Citric Ac13$2,235
Pantoprazole Sodium75$1,536
Esomeprazole Magnesium28$1,039
Rabeprazole Sodium12$575
Lansoprazole17$460
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl16$276
Prednisone11$26

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Braintree Laboratories, Inc.Sutab$301$12,27677 claims
Ferring Pharmaceuticals Inc.Clenpiq$224$2,23513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Bronxville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →